Fludarabine is a purine analog anticancer drug used mainly to treat blood cancers such as chronic lymphocytic leukemia (CLL), and it works by inhibiting DNA synthesis, thereby preventing cancer cell growth and survival; it is particularly effective against lymphoid cells, has strong immunosuppressive properties, and is commonly used in chemotherapy regimens as well as in preparation for stem cell transplantation.
BRAND NAMES
Fludara (most widely recognized international brand)
Oforta (oral form used in some regions)
MECHANISM OF ACTION
Fludarabine is a purine nucleoside analog that interferes with DNA synthesis. After entering the cell, it is converted to its active metabolite (fludarabine triphosphate), which inhibits DNA polymerase, DNA primase, and ribonucleotide reductase. This leads to inhibition of DNA replication and repair, resulting in apoptosis of rapidly dividing lymphoid cells. It is primarily cytotoxic to B-lymphocytes, making it effective in lymphoproliferative disorders.
PHARMACOKINETICS
Absorption
Fludarabine is administered intravenously (most common) or orally (in some formulations). Oral bioavailability is moderate and variable due to rapid conversion to active metabolite.
Distribution
It is widely distributed in body tissues and penetrates malignant lymphocytes effectively. Plasma protein binding is low.
Metabolism
Fludarabine is rapidly dephosphorylated in plasma to 2-fluoro-ara-A, which enters cells and is rephosphorylated to the active triphosphate form.
Elimination
It is primarily eliminated via the kidneys. Dose adjustment is required in renal impairment due to risk of accumulation and toxicity.
PHARMACODYNAMICS
Fludarabine inhibits DNA synthesis in malignant lymphocytes, leading to suppression of tumor growth and induction of apoptosis. It has strong immunosuppressive effects and is highly active in chronic lymphocyticleukemia (CLL) and related hematologic cancers.
ADMINISTRATION
Fludarabine is administered mainly by intravenous infusion. Oral formulations exist in some regions. It is used in chemotherapy regimens and sometimes in stem cell transplant conditioning protocols.
DOSAGE AND STRENGTH
Dosing is based on body surface area and renal function. Careful monitoring is required due to its narrow therapeutic window and risk of myelosuppression.
DRUG INTERACTIONS
Fludarabine has additive immunosuppressive and bone marrow–suppressive effects when combined with other cytotoxic drugs. Combination therapy increases risk of infection and hematologic toxicity.
FOOD INTERACTIONS
No significant food interactions are reported due to intravenous administration in most cases.
CONTRAINDICATIONS
Contraindicated in patients with severe renal impairment (without dose adjustment) and in those with significant bone marrow suppression.
SIDE EFFECTS
Myelosuppression (anemia, neutropenia, thrombocytopenia)
Fever and infections
Nausea and vomiting
Fatigue
Neurological toxicity (in high doses)
OVER DOSAGE
Overdose of fludarabine is a serious medical emergency because it is a highly myelosuppressive and immunosuppressive chemotherapy agent with a narrow therapeutic index. Toxicity is mainly related to excessive exposure of rapidly dividing bone marrow and lymphoid cells.
TOXICITY
Overdose of Fludarabine can cause severe and prolonged bone marrow suppression, leading to life-threatening infections and bleeding. Neurotoxicity (confusion, coma, seizures) may also occur in severe cases. Management is supportive, including infection control, blood transfusions if needed, and hemodialysis may help in reducing drug levels due to renal elimination.
